Moleculin Biotech (NASDAQ:MBRX) Announces Earnings Results

Moleculin Biotech (NASDAQ:MBRX) announced its earnings results on Friday. The company reported ($9.59) EPS for the quarter, missing the consensus estimate of ($8.87) by ($0.72), FiscalAI reports.

Moleculin Biotech Stock Down 1.7%

Shares of Moleculin Biotech stock traded down $0.14 on Friday, hitting $7.92. 9,899 shares of the company traded hands, compared to its average volume of 33,123. The company has a 50-day moving average price of $10.05 and a 200 day moving average price of $37.12. Moleculin Biotech has a 12-month low of $3.23 and a 12-month high of $229.40. The company has a market cap of $8.16 million, a PE ratio of -0.06 and a beta of 2.11.

Analyst Upgrades and Downgrades

MBRX has been the topic of several analyst reports. Wall Street Zen downgraded shares of Moleculin Biotech from a “sell” rating to a “strong sell” rating in a research report on Saturday, November 7th. HC Wainwright reduced their price target on shares of Moleculin Biotech to $60.00 and set a “buy” rating for the company in a research report on Friday, August 28th. Finally, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Moleculin Biotech in a research note on Thursday, October 15th. Two analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. According to MarketBeat.com, the stock presently has a consensus rating of “Hold” and an average target price of $60.00.

About Moleculin Biotech

Moleculin Biotech, Inc. is a clinical-stage pharmaceutical company focused on developing treatments for cancers and other serious diseases. The company uses its proprietary technology platforms to design drug candidates intended to address treatment resistance, improve drug delivery, and target biological pathways involved in disease progression. Moleculin’s lead program is Annamycin, a liposomal formulation of the anthracycline doxorubicin being investigated for acute myeloid leukemia and soft-tissue sarcoma.